Impact of Central Nervous System International Prognostic Index on the Treatment of Diffuse Large B Cell Lymphoma

Background The central nervous system international prognostic index (CNS-IPI) is being used widely for the identification of patients with diffuse large B cell lymphoma (DLBCL) a high risk (CNS) relapse. aim our study to confirm value CNS-IPI in predicting CNS relapse young population and evaluate its impact on selection prophylaxis. Methods We retrospectively reviewed diagnosed DLBCL who were treated rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (RCHOP) regimen from January 2010 till December 2018. Correlation between cumulative incidence time was examined through Kaplan-Meier plots. Median median overall survival after also estimated using Results A total 354 included. age 46 years. Overall, 5% developed seven months. Two-year rates according 0.7%, 5.1%, 26% low, intermediate, high-risk, groups respectively. On multivariate analysis, poor performance status (p=0.045), involvement two or more extranodal sites (p= 0.021), bone marrow 0.029), renal adrenal glands 0.006) significantly correlated Considering high-risk anatomical (breast, uterus, testis, epidural space), would have needed Conclusion Although helps better prophylaxis, it can possibly increase number exposed unnecessary More investigational biomarkers are refining patients.